Stock Analiz

EW vs SNN stock comparison

Edwards Lifesciences vs. Smith & Nephew · data as of November 13, 2026

Edwards Lifesciences (EW) has a market value of about $61.6B, Smith & Nephew (SNN) about $13.1B. Over their latest twelve months Edwards Lifesciences had revenue of $6.7B and Smith & Nephew $6.3B.

On our five checks Edwards Lifesciences scores higher: 2.8 out of 5 (average) against 2.6 (average).

By area, the stronger company is Smith & Nephew on value; Edwards Lifesciences on future growth; Edwards Lifesciences on track record; Edwards Lifesciences on financial health; Smith & Nephew on shareholder returns.

Smith & Nephew is cheaper on earnings (P/E 21.3 vs. 60.5), while Edwards Lifesciences grew revenue faster over five years (6.7% vs. 6.2% a year).

Edwards Lifesciences leads on 13 of the compared lines and Smith & Nephew on 12.

Side by side

EWSNN
Size and price
Market cap$61.6B$13.1B
Share price$107.15$31.28
Score
Overall score (of 5)2.82.6
Value03
Future growth42
Track record21
Financial health53
Shareholder returns34
Valuation
P/E (TTM)60.521.3
Forward P/E33.513.3
Price / free cash flow43.315.3
Price / sales9.22.1
EV / EBITDA35.811.3
PEG8.553.07
DCF value vs. price−64%−17%
Business
Revenue$6.7B$6.3B
Net income$1.0B$635M
Free cash flow$1.4B$855M
Net margin15.3%10.1%
Gross margin (5-yr avg.)79.6%69.5%
ROIC (5-yr avg.)16.0%6.1%
Growth
Revenue growth (1 yr)11.6%6.1%
Revenue growth (5 yrs, per year)6.7%6.2%
EPS growth (5 yrs, per year)7.1%6.9%
Balance sheet and payouts
Net cash (cash minus debt)$3.9B-$2.6B
Dividend yieldNone2.54%
Shareholder yield1.5%6.4%
Analysts
Upside to average target+6%+6%
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: EW TTM to September 30, 2026, SNN TTM to June 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Edwards Lifesciences or Smith & Nephew?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Edwards Lifesciences scores 2.8 out of 5 and Smith & Nephew 2.6; the table shows where each one is stronger.

Is Edwards Lifesciences cheaper than Smith & Nephew?

On trailing earnings, Smith & Nephew trades at a P/E of 21.3 and Edwards Lifesciences at 60.5, so Smith & Nephew is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Edwards Lifesciences or Smith & Nephew?

Over five years Edwards Lifesciences grew revenue about 6.7% a year and Smith & Nephew about 6.2% a year.

Which pays a higher dividend?

Edwards Lifesciences yields nothing (no dividend) and Smith & Nephew 2.54%.

Full Edwards Lifesciences analysis → Full Smith & Nephew analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.